专题：Bladder and Urothelial Cancer Treatments

This cluster of papers focuses on the diagnosis, treatment, and management of bladder cancer, particularly urothelial carcinoma. It covers topics such as chemotherapy, cystectomy, neoadjuvant therapy, molecular characterization, metastatic bladder cancer, guidelines for management, and immunotherapy. The papers provide insights into various aspects of bladder cancer research and clinical practice.
最新文献
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

article Full Text OpenAlex

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) – A Summary of the 2026 Guidelines Update

article Full Text OpenAlex

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma

article Full Text OpenAlex

Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.

article Full Text OpenAlex

Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.

article Full Text OpenAlex

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study

article Full Text OpenAlex

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

article Full Text OpenAlex

A Tumor-Promoting Inflammatory SPP1 + Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer

article Full Text OpenAlex

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

article Full Text OpenAlex

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer

article Full Text OpenAlex

近5年高被引文献
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

article Full Text OpenAlex 1514 FWCI182.6811

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

article Full Text OpenAlex 1122 FWCI421.9454

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 671 FWCI84.7328

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

article Full Text OpenAlex 648 FWCI142.0872

Bladder cancer

review Full Text OpenAlex 554 FWCI46.4947

Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

review Full Text OpenAlex 529 FWCI44.2527

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

article Full Text OpenAlex 528 FWCI125.1582

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

article Full Text OpenAlex 514 FWCI121.3933

Advances in diagnosis and treatment of bladder cancer

article Full Text OpenAlex 505 FWCI189.8754

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment

article Full Text OpenAlex 442 FWCI166.141